Cohera Medical
Pittsburgh, Pennsylvania, United States
About Cohera Medical
Cohera Medical is a medical device company that is actively developing a line of surgical adhesives and sealants. Its products are based on a unique chemical design that is resorbable, non-toxic, easy-to-use and forms a strong bond between tissue layers. The company's lead product, TissuGlu® Surgical Adhesive, is indicated for use in the U.S. for the approximation of tissue planes in abdominoplasty procedures. TissuGlu is currently approved for sale in the EU for the approximation of tissue layers where subcutaneous dead space exists between the tissue planes in large flap surgical procedures such as abdominoplasty and is being utilized in Europe to eliminate drains or reduce complications in patients undergoing large flaps surgical procedures such as abdominoplasty, mastectomy, lymph node dissection, decubitus, and latissimus dorsi flap procedures. Its second product under development, Sylys® Surgical Sealant, the first synthetic sealant designed specifically to help reduce anastomotic leaks, has received CE Mark approval in Europe as an adjunct to standard closure in ileostomy reversal procedures. TissuGlu and Sylys are the first products in a pipeline of technology that includes surgical mesh adhesives, hemostatic foam, bone adhesives, and drug delivery. Sylys and the other Cohera Medical products are currently available for investigational use only and have not yet been approved for sale by the Food and Drug Administration (FDA) in the U.S. or in any other market.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $135.1M
- Funding stage: Private Equity
- Last round: Private Equity (Oct 2015)
- Website: coheramedical.com
- Phone: (412)231-1500
Industries & Categories
Health Care, Manufacturing, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/cohera-medical-2502672 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.